At the 66th Congress of the German Society for Pneumology in Munich, the €5,000 René Baumgart Foundation research prize was awarded to two outstanding researchers working in the field of pulmonary hypertension (full text in German available at this link) English AI translation and summary Dr. Fenja Knöpp (Justus Liebig University, Giessen) was recognised for […]
On 23–24 March 2026, the Alliance for Pulmonary Hypertension attended the Annual Board meeting of ERN-LUNG, the European Reference Network for Rare Respiratory Diseases, in Paris. The Alliance was represented by Louise Bouman, Board member of the organisation and member of the ERN-LUNG E-PAG (European Patient Advisory Group). The meeting brought together healthcare professionals, researchers,
Louise Bouman attended the Pulmonary Vascular Research Institute conference in Dublin on behalf of the Alliance for Pulmonary Hypertension, of which she is a Board Member. You can find her key highlights summary at this link and the full report below. Louise also attended a “Women in Pulmonary Hypertension” lunch, which you can read about
The Pulmonary Vascular Research Institute (PVRI) Congress 2026 will take place in the historic city of Dublin from 28 January – 1 February 2026. ➡️ Explore the full Congress programme at this link The first and last day (28 January and 1 February) will be satellite meetings with the main plenary sessions happening 29-31 January.
The 6th “Journées du Réseau Français de l’Hypertension Pulmonaire” (JRF-HTP), held in October 2024, provided a review of the evolving landscape in pulmonary hypertension (PH). The meeting brought together clinicians and researchers to exchange on the most recent scientific, clinical, and organizational advances in pulmonary hypertension. We are proud that a patient advocate was included as co-author,
Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in
On Monday, 28 September 2025, a State of the Art Session was held at the European Respiratory Society (ERS) Annual Congress 2025 titled: “Pulmonary Hypertension associated with lung diseases: the most burning questions.” The session was chaired by Prof. Dr. Olivier Sitbon, Prof. Dr. David Montani, and Dr. Nesrin Ocal. Leading experts shared the latest
An article titled “The Genesis and Legacy of the NHLBI Patient Registry for the Characterization of Primary Pulmonary Hypertension”, published recently in Pulmonary Circulation, traces the historical development of primary pulmonary hypertension (PPH) research from its first pathological description by Ernest Romberg in 1891 through the establishment of the landmark US National Heart, Lung, and
On Wednesday October 1, 2025, a special programme at the European Respiratory Congress will be discussing what can ERN-LUNG offer for the future. ERN-LUNG is a patient-centric network of European healthcare providers and patient organisations, committed Europe-wide and globally to reducing morbidity and mortality from rare lung diseases in people of all ages through: ✅
Traditionally the World Pulmonary Hypertension Symposia series, started in Geneva in 1973 and held every 5 years after the Evian edition in 1998 (Venice 2003, Dana Point 2008, Nice 2013, Nice 2018), has marked the progresses in pulmonary hypertension science and has anticipated future developments. The published supplement including the symposia proceedings constitutes a collection
Louise Bouman, Chair of Stichting Pulmonale Hypertensie (PHA Netherlands) and Board Member of the Alliance for Pulmonary Hypertension is just back from Amsterdam where she attended the Pulmonary Vascular Institute (PVRI) Symposium on Drug Discovery and Development taking place on June 16-17. “I recently had the opportunity to attend an inspiring symposium organized by the
Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with
An editorial titled “PVRI International Conference 2025: Embracing Heterogeneity”, published in Pulmonary Circulation on May 1, 2025, summarizes the 2025 PVRI International Conference held in Rio de Janeiro, Brazil. The four-day gathering brought together experts from 25 countries across 5 continents to discuss advances in early diagnosis, risk stratification, and treatment approaches for various forms
We were unfortunately unable to attend the European Parliament event which took place on March 5, 2025, but have read the minutes with great interest. Based on these we have put together some key takeaways as this topic is very relevant to pulmonary arterial hypertension patients, who are predominantly women. Opening Member of the European
In the Editor’s Note to “Mariposa” Hall Skaara, project manager at PHA Europe, highlights the organisation’s key 2024 achievements: Download the full issue of the magazine at this link on the PHA Europe website
The annual Board meeting of the ERN-LUNG – European Reference Network for rare respiratory diseases, took place in Paris on March 24-25, 2025, with over 100 participants, not only from the EU but also UK, US and Canada. Two European patient representatives, Pisana Ferrari and Hall Skaara, (2nd and 3rd from left in the cover
The year 2024 has seen significant progress in the fight against pulmonary hypertension, marked by critical milestones across research, clinical care, advocacy, awareness, and patient engagement, with an unprecedented level of patient involvement in scientific discourse. As we head into 2025 with all that has been achieved we are well positioned in furthering our mission!
Stronger Together: Celebrating the Pulmonary Hypertension Community’s 2024 Milestones Read Post »
On Saturday, November 23, 2024, the Dutch National Pulmonary Hypertension Information Day brought together patients, caregivers, and medical professionals for an inspiring and informative symposium. This annual event, designed specifically for pulmonary hypertension patients and their loved ones, offered a full day of learning, connection, and support. The event was expertly chaired by Dr. Sanne
The Sociedad Latina de Hipertensión Pulmonar SLHP, the Colegio Médico del Perú Región Lima and the pulmonary hypertension patient association “Llapan Kallpa”, are inviting to the ,The International Symposium on Pulmonary Hypertension and the 9th meeting of Latin American leaders being held on 6-7 December, with the participation of esteemed professionals including Dr. Pilar Escribano,
The videos of the presentations and recorded sessions from the PHA Europe Annual Pulmonary Hypertension European Conference (APHEC) 2024, held in Castelldefels, Barcelona, Spain, are now available on the Bel Air Center platform. 1. Prof. Ardeschir Ghofrani: Current and future pulmonary hypertension treatments 2. Prof. Polona Mlakar: Chronic thromboembolic pulmonary hypertension (CTEPH) 3. Prof. Mona
